Document Detail

Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen.
MedLine Citation:
PMID:  19171585     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: To ensure that each newborn receives an equitable test of the highest possible sensitivity, we recognized the necessity to reassess immunoreactive trypsinogen and DNA issues in cystic fibrosis newborn screening algorithms. Our objectives included clarification of various factors that influence immunoreactive trypsinogen concentrations and resolution of long-standing questions about variations in immunoreactive trypsinogen levels among newborns. METHODS: Immunoreactive trypsinogen data on 660443 newborns who were born between July 1, 1994, and June 30, 2004, were abstracted from the Wisconsin State Laboratory of Hygiene databases and deidentified for analysis. Using a compiled data set, we analyzed various demographic characteristics to determine their role, if any, in immunoreactive trypsinogen variation. Specifically, season of birth, reagent lot, and birth weight were examined. Sensitivities of the most common cystic fibrosis newborn screening protocols, namely immunoreactive trypsinogen/immunoreactive trypsinogen and immunoreactive trypsinogen/DNA, were also investigated. RESULTS: Mean and 95th percentile immunoreactive trypsinogen levels were shown to vary by both season and reagent lot number and affect sensitivity of the assay. Low birth weight infants had significantly higher immunoreactive trypsinogen values than normal birth weight infants. Sensitivities were also found to vary on the basis of the algorithm used, with the highest sensitivity of 96.2% calculated for an immunoreactive trypsinogen/DNA protocol with 23 cystic fibrosis transmembrane conductance regulator mutation analyses compared with 80.2% with the immunoreactive trypsinogen/immunoreactive trypsinogen method used in 9 states. CONCLUSIONS: Floating, rather than fixed, cutoff values for the initial immunoreactive trypsinogen portion of any cystic fibrosis newborn screening protocol are generally necessary on the basis of the seasonal and reagent lot variations observed. Because of its lower sensitivity, immunoreactive trypsinogen/immunoreactive trypsinogen does not optimize detection of patients with cystic fibrosis.
Molly Kloosterboer; Gary Hoffman; Michael Rock; William Gershan; Anita Laxova; Zhanhai Li; Philip M Farrell
Related Documents :
11134565 - Alloimmunization in preterm infants after repeated transfusions of wbc-reduced rbcs fro...
1238055 - Rupture of the spleen in erythroblastosis fetalis.
892965 - Cystic fibrosis in the netherlands.
7104595 - Absent vas deferens in association with renal abnormalities.
6894845 - Extrahepatic biliary atresia. morphological study of 98 biliary remnants.
9794675 - Risk of low birth weight infants among black and white parents.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pediatrics     Volume:  123     ISSN:  1098-4275     ISO Abbreviation:  Pediatrics     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-01-27     Completed Date:  2009-03-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376422     Medline TA:  Pediatrics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e338-46     Citation Subset:  AIM; IM    
Departments of Population Health Sciences, University of Wisconsin, Madison, WI 53726-2397, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cystic Fibrosis / blood*,  diagnosis*
Infant, Newborn
Neonatal Screening / standards*
Sensitivity and Specificity
Trypsinogen / blood*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reference ranges for hematocrit and blood hemoglobin concentration during the neonatal period: data ...
Next Document:  Transition from pediatric to adult care: internists' perspectives.